JPH062676B2 - Preventive agent for fish diseases consisting of water-soluble glucan - Google Patents
Preventive agent for fish diseases consisting of water-soluble glucanInfo
- Publication number
- JPH062676B2 JPH062676B2 JP1039954A JP3995489A JPH062676B2 JP H062676 B2 JPH062676 B2 JP H062676B2 JP 1039954 A JP1039954 A JP 1039954A JP 3995489 A JP3995489 A JP 3995489A JP H062676 B2 JPH062676 B2 JP H062676B2
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- fish
- water
- scleroglucan
- preventive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001503 Glucan Polymers 0.000 title claims description 25
- 230000003449 preventive effect Effects 0.000 title claims description 8
- 208000010824 fish disease Diseases 0.000 title description 11
- 229920002305 Schizophyllan Polymers 0.000 claims description 15
- 241000251468 Actinopterygii Species 0.000 claims description 14
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims description 11
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 241000252233 Cyprinus carpio Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 241000276707 Tilapia Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920000519 Sizofiran Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229950001403 sizofiran Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 241000604754 Flexibacter Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001492414 Marina Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Farming Of Fish And Shellfish (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、β−１，３−グルコシド結合からなる主鎖を
持つ水溶性グルカン（以下該グルカンと略称する）を有
効成分とする魚病の予防剤（魚類の免疫調節剤）に関す
るものである。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a fish disease containing a water-soluble glucan having a main chain composed of β-1,3-glucoside bonds (hereinafter abbreviated as glucan) as an active ingredient. The present invention relates to a preventive agent (immunomodulator for fish).
従来、各種のキノコから抽出された多糖類が、人間を含
む哺乳動物の免疫能を増強することが知られている。こ
れらの多糖類は、主としてβ−１，３−グルコシド結合
からなる主鎖にβ−１，６−グルコシド結合で分岐した
側鎖を持つグルカンである。Conventionally, it has been known that polysaccharides extracted from various mushrooms enhance the immunity of mammals including humans. These polysaccharides are glucans having a main chain mainly composed of β-1,3-glucoside bonds and side chains branched by β-1,6-glucoside bonds.
また、魚病に対してはワクチンによる防御方法や、抗生
物質による治療方法が知られている。さらに免疫増強活
性にもとづく魚病の予防・治療剤としてＦＫ−５６５
（特開昭６３−２３３９２３号）が知られているが、本
発明で利用するグルカンをこのような技術分野に利用す
ることは今までに知られていない。In addition, a method for protecting against fish disease by a vaccine and a method for treating with an antibiotic are known. Furthermore, FK-565 as a prophylactic / therapeutic agent for fish diseases based on immunopotentiating activity
(JP-A-63-233923) is known, but it has not been known so far to utilize the glucan used in the present invention in such a technical field.
海洋資源の高度利用を目的として、近年多くの魚類の養
殖が広く行なわれるようになってきている。In recent years, many fish have been cultivated for the purpose of advanced utilization of marine resources.
しかしながら魚類の養殖においては、しばしば細菌性又
はウィルス性の魚病が発生し、それらによる損失は莫大
なものであるという報告がしばしばなされている。However, it is often reported that bacterial or viral fish diseases frequently occur in fish farming and the losses caused by them are enormous.
このような魚病の予防（或は治療）を行うために、多く
の薬剤が開発され、部は既に利用されている。その薬剤
の主体となるものは、抗生物質である。In order to prevent (or treat) such fish diseases, many drugs have been developed and some of them have already been used. The main body of the drug is an antibiotic.
しかしながら、抗生物質は、耐性菌の出現とか、抗生物
質の人体への移行というような問題があって、近年その
適用が規制される傾向にある。However, antibiotics have problems such as the emergence of resistant bacteria and the transfer of antibiotics to the human body, and their application tends to be restricted in recent years.
一方、病原菌の死菌を利用したワクチンの利用も一部試
みられているが、適用可能な魚種が限られているため、
新たな薬剤の出現が望まれている。On the other hand, there are some attempts to use vaccines that use killed pathogens, but because the applicable fish species are limited,
The emergence of new drugs is desired.
本発明者は、このような事情に鑑み、抗生物質以外の魚
病の予防剤、例えばワクチンの効果増強剤（アジュバン
ト）について研究を続け、本発明を完成した。In view of such circumstances, the present inventor has continued research on a preventive agent for fish diseases other than antibiotics, for example, an effect enhancer (adjuvant) for vaccines, and completed the present invention.
すなわち、本発明者は前記の目的のために、既に人間に
対して免疫調節効果を示す多くの生体反応修飾物質（Bi
ological Response Modiier）について、それらが魚類
に対し適用可能か否かを鋭意研究した結果、β−１，３
−グルコシド結合からなる主鎖を持ち、且つ水溶性であ
る多糖類が、特に強い魚病の予防活性を有することを見
出した。That is, for the above-mentioned purpose, the present inventor has found that many biological response modifiers (Bi
As a result of diligent research on whether or not they are applicable to fishes, the results of β-1,3
-It has been found that a water-soluble polysaccharide having a main chain composed of glucoside bonds has a particularly strong preventive activity against fish diseases.
本発明は、β−１，３−グルコシド結合からなる主鎖を
持つ水溶性グルカンを有効成分として含有する魚類の細
菌感染症又はウイルス感染症予防・治療剤を提供するも
のである。The present invention provides a prophylactic / therapeutic agent for fish bacterial infections or viral infections, which comprises, as an active ingredient, a water-soluble glucan having a main chain of β-1,3-glucoside bonds.
本発明はまた、β−１，３−グルコシド結合からなる主
鎖を持つ水溶性グルカンを有効成分として含有する魚類
の免疫増強剤を提供するものである。The present invention also provides a fish immunity enhancer containing, as an active ingredient, a water-soluble glucan having a main chain composed of β-1,3-glucoside bonds.
以下、本発明を更に詳細に説明する。Hereinafter, the present invention will be described in more detail.
本発明に於ては、β−１，３−グルコシド結合からなる
主鎖を持つ、水溶性グルカンを使用する。In the present invention, a water-soluble glucan having a main chain composed of β-1,3-glucoside bonds is used.
該グルカンは、特定の担子菌（Schizophyllum commune
Fries）、あるいは該担子菌以外のある種の菌（Sclerot
ium）を液内培養することにより得られることが知られ
ている。該グルカンはβ−１，３−グルコシド結合から
なる主鎖にβ−１，６−グルコシド結合で分岐した側鎖
を持つのが一般的であり、この側鎖の存在によって該グ
ルカンは水溶性となっている。ところでβ−１，３−グ
ルコシド結合の主鎖を持つグルカンの中には、カードラ
ン、ラミナリン等で例示されるような側鎖を持たないも
のがいくつか知られている。このようなβ−１，３−グ
ルカンは、水に一般に不溶性であり、それ故活性は一般
に弱い。しかしながら、これら水不溶性β−１，３−グ
ルカンを化学的に修飾して水溶性としたとき、活性の発
現されることが確認された。The glucan is a specific basidiomycete (Schizophyllum commune
Fries), or certain fungi other than the basidiomycete (Sclerot
It is known that it can be obtained by submerged culture of (ium). The glucan generally has a side chain branched by a β-1,6-glucoside bond in a main chain composed of β-1,3-glucoside bonds, and the presence of this side chain renders the glucan soluble in water. Has become. By the way, among glucans having a β-1,3-glucoside bond main chain, some glucans having no side chain as exemplified by curdlan and laminarin are known. Such β-1,3-glucans are generally insoluble in water and therefore generally weakly active. However, it was confirmed that when these water-insoluble β-1,3-glucan was chemically modified to be water-soluble, the activity was expressed.
該グルカンとしては、次の一般式で示すようなシゾフィ
ラン（特許公告４６−３７８７３号）及びスクレログル
カン（ＵＳＰ1,061,043）を例示することが出来る。Examples of the glucan include schizophyllan (Patent Publication No. 46-37873) and scleroglucan (USP 1,061,043) represented by the following general formula.
なお、グルカンに関連する特許としては、米国特許4,09
8,661（１９７８年７月４日）、英国特許（１９６３年
１０月２３日）及びカナダ特許（１９７５年５月２７
日）等を挙げることができ、これらの公知刊行物に記載
の方法及び化合物は、必要により本発明の一部を構成す
るものとする。 As a patent related to glucan, US Pat.
8,661 (July 4, 1978), British patent (October 23, 1963) and Canadian patent (May 27, 1975).
Date), etc., and the methods and compounds described in these publicly known publications form part of the present invention as necessary.
本発明に於て、グルカンは、水溶液濃度0.01〜１％に於
て使用する。In the present invention, glucan is used at an aqueous solution concentration of 0.01 to 1%.
該水溶液は魚の種類によって、海水に相応する程度まで
の塩を含有していてもよい。Depending on the type of fish, the aqueous solution may contain salts up to an extent corresponding to seawater.
投与方法としては、経口投与法、腹腔・筋肉内注射法、
又は浸漬法等による。経口投与は魚餌と一緒であっても
よい。As an administration method, an oral administration method, an intraperitoneal / intramuscular injection method,
Or by the dipping method or the like. Oral administration may be with fish feed.
さらにその投与量は0.1mg〜２０mg／kg（体重）の割合
とすることが望ましい。Furthermore, the dose is preferably 0.1 mg to 20 mg / kg (body weight).
本発明が適用される魚病としては、例えばハマチ、タ
イ、ヒラメ、フグ、アユ、コイ、ティラピア、ニジマ
ス、ウナギ等のビブリオ症（ビブリオ・アンギュイラル
ム）、類結節症（パスツーレラ・ビスシシーダ）、連鎖
球菌症（ストレプトコッカス・エスピー）、ノカルジア
症（ノカルジア・カンパチー）、滑走細菌症（フレキシ
バクター・マリナス）、エドワジュラ症（エドワジェラ
・タルダ）、エロモナス症（エロモナス・ハイドロフィ
ラ）等の各種細菌感染症、腹水症、リンホシスチス症、
口白症等のウィルス感染症等が挙げられる。Examples of the fish disease to which the present invention is applied include vibrio symptom (Vibrio anguillarum) such as yellowtail, Thailand, flounder, puffer fish, sweetfish, carp, tilapia, rainbow trout, eel, etc., nodular disease (pasteurella viscissida), streptococcus. Aseptic disease (Streptococcus sp.), Nocardiosis (Nocardia campathy), gliding bacterium (Flexibacter marinas), edwajurosis (Edwajera tarda), eromonas (eromonas hydrophila) and other bacterial infections, ascites , Lymphosis,
Examples thereof include viral infections such as stomatosis.
実施例１ コイとティラピアのエドワジェラ症に対する効果 方 法 水温２５℃で飼育した平均体重３０ｇのコイと平均体重
５５ｇのティラピアに、実験開始初日と４日目に、シゾ
フィランまたはスクレログルカンを体重１kg５mgの割合
で腹腔内投与（濃度0.1％生理食塩水溶液）した。なお
対照魚には生理食塩水のみを投与した。ついで、７日目
に魚体通過エドワジェラ・タルダ(Edwardsiella tarda)
を1.5×１０7cfu／尾接種して感染させた。夫々につき
１、２、３、４及び５日後の生存率を調べた。Example 1 Effect of carp and tilapia on edwagerosis Method Carp carp of average weight 30 g and tilapia of average weight 55 g bred at water temperature of 25 ° C. were treated with sizofiran or scleroglucan of weight 1 kg 5 mg on the first day and the fourth day of the experiment. It was intraperitoneally administered at a ratio of 0.1% physiological saline solution. The control fish received physiological saline only. Then, on the 7th day, the fish passed by Edwardiella tarda.
Were infected with 1.5 × 10 7 cfu / tail. The survival rate after 1, 2, 3, 4 and 5 days was examined for each.
結 果 コイにエドワジェラ・タルダを感染させた場合のシゾフ
ィラン投与群、スクレログルカン投与群及び対照群の生
存率（％）を第１表に示した。Results Table 1 shows the survival rates (%) of the Schizophyllan-administered group, the scleroglucan-administered group and the control group when the carp was infected with Edwajella tarda.
ティラピアにエドワジェラ・タルダを感染させた場合の
シゾフィラン投与群、スクレログルカン投与群及び対照
群の生存率（％）を第２表に示した。 Table 2 shows the survival rates (%) of the sizofiran-administered group, the scleroglucan-administered group, and the control group when Tilapia was infected with Edwajera tarda.
実施例２ コイ血中の補体第３成分（Ｃ３）含量の変化 方 法 実施例１と同様にして、コイにシゾフィランとスクレロ
グルカンを投与した。７日目に尾静脈から採血し、血中
のＣ３含量を測定した。 Example 2 Method for Changing Content of Third Component of Complement (C3) in Carp Blood In the same manner as in Example 1, carp carp was administered sizofiran and scleroglucan. On the 7th day, blood was collected from the tail vein and the C3 content in blood was measured.
結 果 シゾフィラン及びスクレログルカン投与後のコイ血中の
補体第３成分（Ｃ３）含量（u/ml)*を第３表にまとめて
示す。Results Table 3 shows the contents of the third component of complement (C3) (u / ml) * in carp blood after administration of sizofiran and scleroglucan.
＊ ３×107個の感作ヒツジ赤血球の50％を溶血させる
Ｃ３量を１単位（１ｕ）と規定した。 * The amount of C3 that causes hemolysis of 50% of 3 × 10 7 sensitized sheep red blood cells was defined as 1 unit (1 u).
参考例３ ワクチン投与後のコイの血中凝集抗体価の変化 方 法 水温２５℃で飼育したコイに、エドワジェラ・タルダ死
菌ワクチン0.1mg湿重量／尾と、シゾフィラン又はスク
レログルカン５０μｇ／尾とを混合接種し、５、１０、
１５日後の血中凝集抗体価を測定した。Reference Example 3 Method of Change in Blood Aggregation Antibody Titer of Carp after Vaccine Administration Method Carp bred at a water temperature of 25 ° C. were treated with Edwagera tarda killed vaccine 0.1 mg wet weight / tail and Schizophyllan or scleroglucan 50 μg / tail. Mixed inoculation with 5, 10,
The blood aggregation antibody titer was measured after 15 days.
結 果 血中凝集抗体価の経日変化を第４表にまとめて示す。Results Table 4 shows the daily changes in the titer of antibody in the blood.
〔発明の効果〕 実施例１及び２の結果から明らかなように、コイ及びテ
ィラピアにシゾフィラン又はスクレログルカンを投与す
ると、魚病、例えばエドワジェラ・タルダ感染時の生存
率が高まる。すなわち魚病の予防剤として有効である。
これらの多糖類、グルカンは感染初期に効果を発揮し、
又、血中のＣ３含量を増大させることから、非特異的免
疫機構（補体、食細胞等）の活性化に関与していると考
えられる。 [Effect of the invention] As is clear from the results of Examples 1 and 2, when Schizophyllan or scleroglucan is administered to carp and tilapia, the survival rate of fish diseases, for example, Edwagela tarda infection is increased. That is, it is effective as a preventive agent for fish diseases.
These polysaccharides, glucan, are effective in the early stages of infection,
Also, since it increases the C3 content in blood, it is considered to be involved in the activation of non-specific immune mechanisms (complement, phagocytes, etc.).
さらに参考例３において、エドワジェラ・タルダ死菌ワ
クチンと、シゾフィラン（又はスクレログルカン）とを
混合接種した際、凝集抗体価がワクチンの単独投与の場
合より高くなっていることから、これらの多糖類、グル
カンがアジュバンド活性を有することが明らかである。Furthermore, in Reference Example 3, when the vaccine of killed Evdagera tarda bacillus and Schizophyllan (or scleroglucan) are mixed and inoculated, the agglutinating antibody titer is higher than that in the case of single administration of the vaccine. , It is clear that glucan has adjuvant activity.
さらに、ワクチンで処理された魚に、後日（すなわち免
疫後）、該グルカンを投与してもアジュバント活性のあ
ることが確認された。Furthermore, it was confirmed that the vaccine-treated fish had adjuvant activity even after administration of the glucan at a later date (that is, after immunization).
Claims (6)
を持つ水溶性グルカンを有効成分として含有する魚類の
細菌感染症又はウイルス感染症予防・治療剤。1. A preventive / therapeutic agent for fish bacterial infections or viral infections, which comprises, as an active ingredient, a water-soluble glucan having a main chain of β-1,3-glucoside bonds.
記載の予防・治療剤。2. The glucan is schizophyllan (1)
The preventive / therapeutic agent described.
(1)記載の予防・治療剤。3. The glucan is scleroglucan.
(1) The preventive / therapeutic agent described.
を持つ水溶性グルカンを有効成分として含有する魚類の
免疫増強剤。4. A fish immunity enhancer containing, as an active ingredient, a water-soluble glucan having a main chain composed of β-1,3-glucoside bonds.
記載の免疫増強剤。5. The glucan is schizophyllan (4)
The described immune enhancer.
(4)記載の免疫増強剤。6. The glucan is scleroglucan.
(4) The immunopotentiator according to the above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1039954A JPH062676B2 (en) | 1989-02-20 | 1989-02-20 | Preventive agent for fish diseases consisting of water-soluble glucan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1039954A JPH062676B2 (en) | 1989-02-20 | 1989-02-20 | Preventive agent for fish diseases consisting of water-soluble glucan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02218615A JPH02218615A (en) | 1990-08-31 |
| JPH062676B2 true JPH062676B2 (en) | 1994-01-12 |
Family
ID=12567350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1039954A Expired - Fee Related JPH062676B2 (en) | 1989-02-20 | 1989-02-20 | Preventive agent for fish diseases consisting of water-soluble glucan |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH062676B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008255138A (en) * | 2007-03-30 | 2008-10-23 | Kobayashi Pharmaceut Co Ltd | Th1/Th2 BALANCE-IMPROVING AGENT |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2911554B2 (en) * | 1990-06-25 | 1999-06-23 | 台糖株式会社 | Antiviral agent |
| JPH0665649B2 (en) * | 1991-02-01 | 1994-08-24 | 台糖株式会社 | Crustacean biological defense enhancer, infectious disease preventive vaccine and feed |
| US5786343A (en) * | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
| DE19911053B4 (en) * | 1999-03-12 | 2004-10-28 | Biotec Asa | Cosmetic and / or pharmaceutical preparations |
| DE19917744A1 (en) * | 1999-04-20 | 2000-10-26 | Cognis Deutschland Gmbh | Decorative cosmetic preparation, e.g. face cream, rouge or lipstick, contains beta-(1,3)-glucan having e.g. moisture retaining, anti-wrinkling and immunostimulant effects to improve care properties |
| WO2003018051A1 (en) * | 2001-08-27 | 2003-03-06 | Vic Jira | Anti-fungal composition |
| GB0225502D0 (en) * | 2002-11-01 | 2002-12-11 | Zoolife Internat Ltd | Therapeutic and prophylactic preparations |
| JP4863615B2 (en) * | 2004-12-16 | 2012-01-25 | 日清丸紅飼料株式会社 | Functional fish feed |
| CA2706620C (en) | 2007-11-26 | 2018-02-27 | Novartis Ag | Conjugated beta-1,3-linked glucans |
| US20100266626A1 (en) * | 2007-11-26 | 2010-10-21 | Francesco Berti | Adjuvanted glucans |
| CN110692558B (en) * | 2019-11-13 | 2021-08-06 | 扬州科润德机械有限公司 | Fish swarm epidemic prevention method |
| CN117378707A (en) * | 2023-10-08 | 2024-01-12 | 广东海大集团股份有限公司 | A kind of premixed feed that promotes fish growth and improves immunity and its application |
| WO2025206309A1 (en) * | 2024-03-29 | 2025-10-02 | 株式会社ニッスイ | Method for treating or preventing bacterial disease in fish |
-
1989
- 1989-02-20 JP JP1039954A patent/JPH062676B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008255138A (en) * | 2007-03-30 | 2008-10-23 | Kobayashi Pharmaceut Co Ltd | Th1/Th2 BALANCE-IMPROVING AGENT |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02218615A (en) | 1990-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2828799B2 (en) | Method for producing yeast glucan | |
| Newman | Mannan-oligosaccharides: natural polymers with significant impact on the gastrointestinal microflora and the immune system. | |
| US5322841A (en) | Method for producing neutral glucans for pharmaceutical applications | |
| JP2911554B2 (en) | Antiviral agent | |
| JPH062676B2 (en) | Preventive agent for fish diseases consisting of water-soluble glucan | |
| JPH05502018A (en) | Immune system activation method | |
| EP0384323B2 (en) | Composition and process to enhance the efficacy of a fish vaccine | |
| US5189028A (en) | Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish | |
| US5641761A (en) | Preventive agent against infectious disease of crustacea | |
| JP3522772B2 (en) | Vaccine immunopotentiator | |
| JP3649787B2 (en) | Prophylactic agent for enterococcal infection in fish and use thereof | |
| EP1594418A2 (en) | Immunopotentiating agent for use in animals | |
| US5503830A (en) | Compounds having immunostimulating activity and methods of use thereof | |
| WO2000032213A1 (en) | ηδT CELL IMMUNOACTIVITY POTENTIATORS CONTAINING SHIITAKE MUSHROOM HYPHA EXTRACT | |
| JPH06271470A (en) | Immunostimulating agent for fish | |
| JP2001342140A (en) | Medicine and feed for fish and crustacean | |
| JP2005060288A (en) | Immunostimulant and antitumor agent | |
| US20240148778A1 (en) | Glycoside inhibitors of yeast | |
| Dalmo | Immunostimulatory β (1, 3)-D-glucans; prophylactic drugs against threatening infectious diseases of fish | |
| Gannam | β‐Glucans | |
| JP2001342141A (en) | Medicine and feed for aquatic animal and land animal | |
| Killeen et al. | The potential of polysaccharide supplements in diets for livestock and pets. | |
| Balicka-Ramisz et al. | Practical application of chitosan in pig’production. | |
| JPWO2000057719A1 (en) | Feed additives and feed for crustaceans or fish | |
| JPWO2001064245A1 (en) | Immuno-enhancing composition and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |